Skip to content

Mathan Thailam for the Management of Varicose Ulcer

An Open ,Non Randomised, Single Centric Clinical Trial To Evaluate the Effectiveness of Mathan Thailam in the Management of Naala Viranam( Varicose Ulcer)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048775
Enrollment
20
Registered
2023-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I832- Varicose veins of lower extremities with both ulcer and inflammation

Interventions

Intervention1: MATHAN THAILAM: WOUND DRESSING WILL DONE DAILY FOR 48 DAYS Control Intervention1: not applicable: not applicable

Sponsors

NATIONAL INSTITUTE OF SIDDHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willingness to participate in trial and signing consent by fulfilling the condition of Proforma 2.Presence of venous ulcer 3.Confirmation of venous incompetence through venous doppler study 4.Willing to give specimen of blood for the investigation 5.Permit to take photograph 6.Willing to participate in trial and signing consent by fulfilling the condition of Proforma

Exclusion criteria

Exclusion criteria: 1.History of connective tissue disorders 2.Uncontrolled co morbidities 3.History of contagious diseases 4.History of Malignancy 5.History of hypersensitivity reactions to the study drug or its ingredients 6.Participants from vulnerable groups

Design outcomes

Primary

MeasureTime frame
The Outcome of the treatment will be observed by Venous clinical severity score (VCSS) Timepoint: 48 days

Secondary

MeasureTime frame
Quality of Life by Dermatology Life Quality Index (DLQI) Timepoint: 48 Days

Countries

India

Contacts

Public ContactSubhashri R

NATIONAL INSTITUTE OF SIDDHA

mahasiddha2009@gmail.com9840417565

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026